NASDAQ:ARTL Artelo Biosciences (ARTL) Stock Price, News & Analysis $4.69 -0.13 (-2.70%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$4.70 +0.01 (+0.32%) As of 10/3/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Artelo Biosciences Stock (NASDAQ:ARTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Artelo Biosciences alerts:Sign Up Key Stats Today's Range$4.66▼$4.8550-Day Range$4.35▼$13.9352-Week Range$4.20▼$28.60Volume35,753 shsAverage Volume108,494 shsMarket Capitalization$3.28 millionP/E RatioN/ADividend YieldN/APrice Target$24.00Consensus RatingHold Company Overview Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes. The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia. In parallel, Artelo is advancing AB188, a topical formulation aimed at treating ocular surface diseases such as dry eye syndrome. Earlier-stage preclinical candidates are being explored for inflammatory and cardiometabolic indications, reflecting the versatility of Artelo’s platform technology in shaping molecular properties to target diverse disease pathways. Founded as a Delaware corporation, Artelo Biosciences is headquartered in Cleveland, Ohio, and conducts research and development activities in the United States. The executive leadership team brings together expertise in medicinal chemistry, pharmaceutical development and regulatory strategy. Artelo continues to engage with key opinion leaders and strategic partners to support its pipeline through proof-of-concept studies and toward eventual regulatory filings.AI Generated. May Contain Errors. Read More Artelo Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreARTL MarketRank™: Artelo Biosciences scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingArtelo Biosciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialArtelo Biosciences has a consensus price target of $24.00, representing about 411.7% upside from its current price of $4.69.Amount of Analyst CoverageArtelo Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Artelo Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Artelo Biosciences are expected to grow in the coming year, from ($2.62) to ($1.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artelo Biosciences is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artelo Biosciences is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtelo Biosciences has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Artelo Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.25% of the float of Artelo Biosciences has been sold short.Short Interest Ratio / Days to CoverArtelo Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artelo Biosciences has recently increased by 82.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtelo Biosciences does not currently pay a dividend.Dividend GrowthArtelo Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.25% of the float of Artelo Biosciences has been sold short.Short Interest Ratio / Days to CoverArtelo Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artelo Biosciences has recently increased by 82.88%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.04 News SentimentArtelo Biosciences has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Artelo Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ARTL on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Artelo Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Artelo Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.80% of the stock of Artelo Biosciences is held by insiders.Percentage Held by InstitutionsOnly 0.87% of the stock of Artelo Biosciences is held by institutions.Read more about Artelo Biosciences' insider trading history. Receive ARTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTL Stock News HeadlinesArtelo Biosciences Announces Closing of $2.0 Million Public OfferingOctober 1, 2025 | globenewswire.comArtelo Biosciences Announces Pricing of $2.0 Million Public OfferingSeptember 30, 2025 | globenewswire.comMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on some of the biggest winners of 2025.October 5 at 2:00 AM | Chaikin Analytics (Ad)Artelo Biosciences files to sell common stock, no amount givenSeptember 29, 2025 | msn.comArtelo Biosciences, Inc. Announces Underwritten Public Offering of Common Stock and Pre-Funded WarrantsSeptember 29, 2025 | quiverquant.comQArtelo Biosciences Announces Proposed Underwritten Public OfferingSeptember 29, 2025 | globenewswire.comArtelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society ConferenceSeptember 29, 2025 | globenewswire.comArtelo Biosciences, Inc. (NASDAQ:ARTL) Receives Average Recommendation of "Buy" from AnalystsSeptember 28, 2025 | americanbankingnews.comSee More Headlines ARTL Stock Analysis - Frequently Asked Questions How have ARTL shares performed this year? Artelo Biosciences' stock was trading at $6.36 at the beginning of the year. Since then, ARTL stock has decreased by 26.3% and is now trading at $4.69. How were Artelo Biosciences' earnings last quarter? Artelo Biosciences, Inc. (NASDAQ:ARTL) posted its earnings results on Wednesday, August, 13th. The company reported ($5.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $5.48. When did Artelo Biosciences' stock split? Artelo Biosciences's stock reverse split on the morning of Friday, June 13th 2025.The 1-6 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. How do I buy shares of Artelo Biosciences? Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artelo Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/13/2025Today10/05/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARTL CIK1621221 Webwww.artelobio.com Phone(858) 925-7049FaxN/AEmployees5Year Founded2017Price Target and Rating Average Price Target for Artelo Biosciences$24.00 High Price Target$30.00 Low Price Target$18.00 Potential Upside/Downside+411.7%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($19.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.83 million Net MarginsN/A Pretax MarginN/A Return on Equity-497.68% Return on Assets-213.76% Debt Debt-to-Equity RatioN/A Current Ratio0.39 Quick Ratio0.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.31 per share Price / Book0.88Miscellaneous Outstanding Shares700,000Free Float663,000Market Cap$3.28 million OptionableNot Optionable Beta1.41 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ARTL) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.